T1	Participants 607 792	2-arm approaches with a comparison of continuous standard therapy based on the CAV- or CMC-protocol with an alternating schedule often consisting of the CAV- or CMC-derived combinations
T2	Participants 806 852	regimen including cisplatinum and/or etoposide
T3	Participants 28 50	small cell lung cancer
T4	Participants 255 297	large series of trials since the late 70's
T5	Participants 1251 1328	3-arms approaches using both alternating protocols as continuous control arms
